Lu W, et al. (2015) SKP2 inactivation suppresses prostate tumorigenesis by mediating JARID1B ubiquitination. Oncotarget 6, 771-88 25596733

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

K242-ub - JARID1B (human) ▲

Modsite: RAEAMNIkIEPEETT SwissProt Entrez-Gene Orthologous residues JARID1B (human): K242‑ub, JARID1B iso2 (human): K278‑ub, JARID1B (mouse): K242‑ub, JARID1B (rat): K242‑ub Characterization Methods used to characterize site in vivo:  immunoassay, immunoprecipitation, mutation of modification site, western blotting Disease tissue studied:  prostate cancer Relevant cell lines - cell types - tissues:  HEK293T (epithelial), PC3 (prostate cell) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes UBIQUITIN LIGASE TRAF6 (human) microscopy-colocalization, inhibition of upstream enzyme, transfection of inactive enzyme, co-immunoprecipitation, modification site within consensus motif, transfection of wild-type enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes SKP2 (human) decrease Downstream Regulation Effect of modification (function):  enzymatic activity, induced, intracellular localization Effect of modification (process):  carcinogenesis, inhibited Comments:  decreases H3K4Me3 methylation, induces senescence